1. Taniguchi M, Harada M, Kojo S et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21: 483–513.
2. Smyth MJ, Godfrey DI. NKT cells and tumor immunity – a double-edged sword. Nature Immunol 2000; 1(16): 459–460.
3. Godfrey DI, MacDonald HR, Kronenberg M et al. NKT cells: what‘s in a name? Nat Rev Immunol 2004; 4(3): 231–237.
4. Satoh M, Seki S, Hashimoto W et al. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 1996; 157(9): 3886–3892.
5. Ortaldo JR, Winkler-Pickett RT, Yagita H et al. Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991; 136(2): 486–495.
6. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153(4): 1687–1696.
7. Baxevanis CN, Gritzapis AD, Papamichail M. In vivo antitumor activity of NKT-like cells activated by the combination of IL-12 and IL-18. J Immunol 2003; 171(6): 2953–2959.
8. Baxevanis CN, Gritzapis AD, Tsitsilonis OE et al. HER-2//neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 2002; 98(6): 864–872.
9. Peralbo E, Alonso C, Solana R. Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing. Exp Gerontol 2007; 42(8): 703–708.
10. Stremmel C, Exley M, Balk S et al. Characterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets. Eur J Immunol 2001; 31(9): 2818–2828.
11. Zhou L, Wang H, Zhong X et al. The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells. Genome Biol 2008; 9(7): R119.
12. Lee H, Hong C, Shin J et al. The presence of CD8+ invariant NKT cells in mice. Exp Mol Med 2009; 41(12): 866–872.
13. Hodge G, Hodge S, Li-Liew C et al. Increased natural killer T-like cells are a major source of pro-inflammatory cytokines and granzymes in lung transplant recipients. Respirology 2012; 17(1): 155–163.
14. Jadidi-Niaragh F, Jeddi-Tehrani M, Ansaripour B et al. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol. Epub ahead of print 2012.
15. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005; 10(2): 267–275.
16. Zubieta MR, Furman D, Barrio M et al. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006; 168(5): 1666–1675.
17. Wang H, Yang D, Xu W et al. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients. Immunol Lett 2008; 120(1–2): 65–71.
18. Oppenheim DE, Roberts SJ, Clarke SL et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005; 6(9): 928–937.
19. Schwinn N, Vokhminova D, Sucker A et al. Interferon--gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2009; 124(7): 1594–1604.